News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Subscribe To Our Newsletter & Stay Updated
